Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 29 Dec 2017
At a glance
- Drugs Solanezumab (Primary)
- Indications Cognition disorders
- Focus Registrational; Therapeutic Use
- Acronyms A4
- Sponsors Eli Lilly
- 20 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 03 Aug 2017 Planned End Date changed from 1 Oct 2020 to 1 Jul 2022.
- 03 Aug 2017 Planned primary completion date changed from 1 Oct 2020 to 1 Jul 2022.